Badreddine Moukafih

Badreddine Moukafih

Auto-generated profile, based on publicly available information

Badreddine Moukafih

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
BMBadreddine Moukafih
Badreddine Moukafih
HAHalima Abahssain
Halima Abahssain
HMHind Mrabti
Hind Mrabti
HEHassan Errihani
Hassan Errihani
YRYounes Rahali
Younes Rahali
ACAicha Chaibi
Aicha Chaibi
Background: Clinical pharmacists are contributing to safe medication use by providing comprehensive management to patients and medical staff. The aim of this study is to document and evaluate the role of clinical pharmacy services in oncology department. Patients and methods: A prospective, descriptive, observational study was carried out from July 2018 through June 2019 at the Department of Medical Oncology at the National Institute of Oncology, Morocco. Medication reviews concerning hospitalized adult cancer patients were performed every day by the clinical pharmacist assigned to the department. Results: A total of 3542 prescriptions of 526 adult cancer patients were analyzed. The pharmacist identified 450 drug-related problems (12.7% of the prescriptions) primarily related to the analgesics (31.5%). Medication problems included mostly untreated indications (31.3%), overdosing (17.1%), drug–drug interactions (12.4%), underdosing (11.1%), administration omissions (6.7%), drug not indicated (6.0%), and contraindication (5.3%). Interventions ( n = 450) led to drug additions (30.7%), drug dosing adjustments (27.1%), treatment discontinuations (20.0%), recall of the treatment (6.2%), replacement of a drug with another one (5.1%), administration optimization (4.0%), therapeutic drug monitoring (3.1%), alternate routes of administration (2.5%), and extension of treatment duration (1.3%). Most (98%) of the interventions were accepted and implemented by the medical staff—172 (38.2%) having a significant clinical impact on the patient, 88 (19.6%) as having a very significant clinical impact, and 71(15.8%) as having a potential vital impact. Conclusion: This work highlights the positive clinical relevance of pharmacists’ interventions in oncology and the importance of medicopharmaceutical collaboration to prevent medication error.

20 October 2020 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
MSMohamed Lemine Sow
Mohamed Lemine Sow
HYHind El Yacoubi
Hind El Yacoubi
BMBadreddine Moukafih
Badreddine Moukafih
SBSalif Balde
Salif Balde
GAGloria Akimana
Gloria Akimana
HEHassan Errihani
Hassan Errihani
Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology. The frequency of EGFR mutations is ethnicity-dependent, with a higher proportion reported in Asian populations than Caucasian populations. There is a lack of data on these mutations in north Africa. Tumor specimens from Moroccan patients with NSCLC were collected from five pathology laboratories between November 2010 and December 2017 to determine frequency and types of EGFR mutations. Tumors were tested in a reference center for EGFR by polymerase chain reaction and sequencing of exons 18, 19, 20, and 21. A total of 334 patients were enrolled: 242 (72.5%) males and 92 females (27.5%). A total of 56.9% had a history of smoking. EGFR testing of the 334 lung adenocarcinoma samples demonstrated a wild-type EGFR in 261 (78.1%) and mutated EGFR in 73 (21.9%). Mutations were mainly detected in the exon 19 deletion (65.8%), followed by exon 21 L858 (17.8%) and other exon 21 codon mutations (5.5%) and exon 18 (6.8%), whereas primary mutations of exon 20 were less frequent (4.1%). In patients with advanced NSCLC, the detection of EGFR mutation was independently associated with sex (41.3% female vs 14.5% male; p < 0.001) and smoking status (34.8% nonsmokers vs 12.9% active smokers; p < 0.001). The mean age was significantly different between the two groups (p = 0.041). Our findings confirm the genetic heterogeneity of NSCLC worldwide, reporting frequency of EGFR mutations in Moroccan patients with NSCLC between those of Asian and Caucasian populations.

5 November 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
HAHalima Abahssain
Halima Abahssain
BMBadreddine Moukafih
Badreddine Moukafih
Hajar EssangriHajar Essangri
Hajar Essangri
HMHind Mrabti
Hind Mrabti
BMBouchra Meddah
Bouchra Meddah
HEHassan Errihani
Hassan Errihani
Background: Ifosfamide-induced encephalopathy (IIE) is a rare and serious adverse reaction. Thus far, no standard medication has been documentedto be efficient in the reversal of IIE, and while ifosfamide infusion interruption and hydration are recommended, methylene blue (MB) administration remains controversial. Methods: We retrospectively reviewed medical records to assess cases with IIE after ifosfamide infusion. We included all patients having received an ifosfamide infusion during their hospitalization in the medical oncology unit of the National Institute of Oncology in Rabat, Morocco, between September 2016 and September 2017. We subsequently conducted a literature review to determine the role of MB in IIE by searching PubMed using the terms “Methylene Blue” and “Ifosfamide”. Results: A total of 88 patients received ifosfamide, and four patients had IIE. Ifosfamide infusion was stopped immediately after the IIE occurrence, and patients underwent renal function correction with hydration. All patients received MB infusion, and three patients had an improvement of their neurological status. As regards the literature review, 34 articles were reviewed and 16 items were included in the review. Overall, 38 (65.5%) patients received MB infusion and 28 (75.6%) patients responded favorably to the treatment. Conclusions: Methylene blue can be used as a treatment for IIE owing to the severity of the IIE as well as absence of standard medication. Nonetheless, side effects such as serotonergic syndrome should be investigated. More broadly, prospective studies and controlled trials are needed to explore the contribution of MB in IIE management and encourage its use.

13 September 2022 in Therapies
Verified
Journal Article
Closed access
BMBadreddine Moukafih
Badreddine Moukafih
SMSoufiane El Marrakchi
Soufiane El Marrakchi
IBIsmail Bennani
Ismail Bennani
MLMounia Lakhdar-Idrissi
Mounia Lakhdar-Idrissi
MHMoustapha Hida
Moustapha Hida
SASanae Achour
Sanae Achour

1 May 2020 in Therapies
Verified
Journal Article
Closed access
MSMohamed Lamine Sow
Mohamed Lamine Sow
BMBadreddine Moukafih
Badreddine Moukafih
SBSalif Balde
Salif Balde
SESiham Elkhoyaali
Siham Elkhoyaali
ACAicha Chaibi
Aicha Chaibi
HEHassan Errihani
Hassan Errihani

13 April 2019 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MSM.L. Sow
M.L. Sow
HYH. El Yacoubi
H. El Yacoubi
BMB. Moukafih
B. Moukafih
SBS. Balde
S. Balde
GAG. Akimana
G. Akimana
HEH. Errihani
H. Errihani
Background: Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in adenocarcinoma histology (aNSCLC). The frequency of EGFR mutations is ethnicity-dependent, with a higher proportion in Asian populations than Caucasian populations. Yet there is a lack of data of these mutations among North African patients. The aim of this study was to report the frequency and types of EGFR mutations in a group of NSCLC Moroccan patients.